Thereafter, in HG-induced human retinal capillary endothelial cells (HRCEC), it was found that increased expression of Drp1, decreased expression of MFN2, increased mitochondrial reactive oxygen species (mtROS), and activation of NLRP3 inflammatory vesicles, and decreased protein expression of PINK1, Parkin, and VDAC1, whereas overexpression of VDAC1 could promote PINK1 expression and inhibit the activation of NLRP3, thus it was concluded that VDAC1 may be a potential target for the prevention and treatment of DR [161]
PlexusDx has no commercial relationship with Ivim Health and receives no compensation tied to this article
Neuroscience Research 37 (3): 227-36
Examples include: peptide therapy (at high doses or long-term use) TB-500 (Thymosin Beta-4) VEGF-mimetic peptides Tesamorelin/peptide therapy (via IGF-1 pathways) Potential risks of prolonged use: Scar tissue overdevelopment Feeding abnormal or cancerous cell growth Disrupting blood flow in sensitive tissues (eyes, kidneys) Thats why we recommend cycles like: TB-500 : 610 weeks on, 4+ weeks off peptide therapy injections : short-term, with oral BPC for maintenance Tesamorelin/peptide therapy : rotated or paused to avoid overexposure Other Peptides That Benefit From Cycling Even non-angiogenic peptides benefit from breaks: Thymosin Alpha-1 : 5-week cycles, 23x per year GHK-Cu : 78 week cycles, followed by rest Semax & Dihexa : pulsed use to maintain brain sensitivity 5-Amino-1MQ : cycled after 23 rounds for metabolic reset Each protocol is tailored to half-life, tissue targets, and sensitivity feedback
North Carolina Medicaid has estimated it will spend $16 million a year on GLP-1s
We partner with you to achieve measurable, meaningful results
